编辑丨于靖
近日,Compass Therapeutics公布了其VEGF/DLL4(CTX-009)双特异抗体联合紫杉醇在治疗胆道癌(BTC)的2期临床中期研究成果,结果表明该双抗药物安全性良好,在24名患者中有10位病人平均治疗6个月后得到了客观缓解,ORR为42%(10/24),算不上惊艳,...查看全文
usbiostock2018-08-03 09:49
$OncoMed Pharmaceuticals, Inc. (OMED)$ 1. Navicixizumab单药治疗实体瘤临床1a期试验一线数据预计:2018年第4季度;2. Etigilimab单药治疗进展性/转移性实体瘤临床1a期试验一线数据预计:2018年第4季度;3. 现金:$79.9M。查看全文
$OptMed(OMED)$ RW Registration Withdrawal Request Accession Number: 0000897069-23-000718 Act: NE Size: 6 KB 网页链接
$OptMed(OMED)$ S-1/A [Amend] General form for registration of securities under the Securities Act of 1933 Accession Number: 0001493152-22-020351 Act: 33 Size: 3 MB 网页链接
$Oncomed制药(OMED)$ S-1 General form for registration of securities under the Securities Act of 1933 Accession Number: 0001493152-22-016871 Act: 33 Size: 44 MB 网页链接
$Oncomed制药(OMED)$ 15-12B - Securities registration termination [Section 12(b)] Filed: 2019-05-03 AccNo: 0000950103-19-005954 Size: 11 KB 网页链接
$Oncomed制药(OMED)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2019-04-26 AccNo: 0000921895-19-001178 Size: 202 KB 网页链接
$Oncomed制药(OMED)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2019-04-24 AccNo: 0000950103-19-005050 Size: 22 KB 网页链接
$Oncomed制药(OMED)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2019-04-24 AccNo: 0000950103-19-005051 Size: 22 KB 网页链接
$Oncomed制药(OMED)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2019-04-24 AccNo: 0000950103-19-005052 Size: 22 KB 网页链接
$Oncomed制药(OMED)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2019-04-24 AccNo: 0000950103-19-005053 Size: 22 KB 网页链接
$Oncomed制药(OMED)$ S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments Filed: 2019-04-24 AccNo: 0000950103-19-005054 Size: 22 KB 网页链接